Blog

Courtesy of NAA:

The U.S. Food and Drug Administration’s Center for Veterinary Medicine announced today the approval of additional indications for 35% PEROX-AID for use in freshwater finfish. This approval will help provide a critical treatment for improving fish health. The agency also anticipates that resource management agencies will use this approved treatment for aiding in the restoration of certain freshwater fish populations.
 
35% PEROX-AID was previously approved for the control of mortality in: (1) freshwater-reared finfish eggs due to saprolegniasis, a fungal disease that can cause lesions on the fish’s skin, and in some cases, cause respiratory distress and death; (2) freshwater-reared salmonids due to bacterial gill disease; and (3) freshwater-reared coolwater finfish and channel catfish due to external columnaris disease, a common and often fatal disease for fish that is caused by bacteria in water that can enter a fish’s mouth, gills or a wound.

35% PEROX-AID is now also approved for:

• the control of mortality in freshwater-reared coldwater finfish, fingerling and adult freshwater-reared coolwater finfish, and fingerling and adult freshwater-reared warmwater finfish due to saprolegniasis. This indication allows for the treatment of saprolegniasis in life stages other than eggs; 
• the treatment and control of Gyrodactylus spp. in freshwater-reared salmonids. Gyrodactylus spp. are external parasites of fish, making 35% PEROX-AID a new option for treating parasites on fish; and 
• the control of mortality due to external columnaris in all freshwater-reared warmwater finfish, in addition to the previously approved indication for freshwater-reared coolwater finfish and channel catfish.

In a recent survey conducted by the U.S. Fish and Wildlife Service, Association of Fish and Wildlife Agencies, and National Aquaculture Association, these diseases were identified as top disease concerns for fish. While these diseases can be harmful to fish, they do not affect people.
 
Studies to demonstrate effectiveness for the new indications were conducted by the U.S. Fish and Wildlife Service’s Aquatic Animal Drug Approval Partnership program, the U.S. Geological Service’s Upper Midwest Environmental Science Center, and the Food and Drug Administration Center for Veterinary Medicine’s Office of Research.